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Chronic community and occupational expo-
sures of adults to lead have been associated
with deleterious effects on multiple organ sys-
tems, with consequent impacts on health, such
as renal function impairment, hyperuricemia,
and hypertension (1,2). Recently, attention has
focused on understanding genetic factors that
explain differences in symptoms between indi-
viduals who have had similar lead exposures.
Identiﬁcation of such genes would presumably
help explain variation in the relationship
between biologic markers of lead exposure and
measures of organ dysfunction.
One genetic polymorphism that has been
suggested (3) as a modiﬁer of the pharmaco-
kinetic distribution of lead (and therefore its
toxicity) concerns the alleles that code for the
production of δ-aminolevulinic acid dehy-
dratase (ALAD), which is the second enzyme
in the biosynthetic pathway of heme (4,5). In
1981, Battistuzzi et al. (5) showed that
human ALAD protein is a polymorphic
enzyme. Subsequently, Wetmur et al. (6)
found that this enzyme is polymorphic
because of a G-to-C transversion of
nucleotide 177 in a coding region that results
in replacement of the amino acid lysine with
asparginine. Although no significant differ-
ence was noted in the activities of the ery-
throcyte ALAD 1-1, ALAD 1-2, or ALAD
2-2 (5), Bergdahl et al. (3) reported that the
ALAD-2 subunit binds lead more tightly than
does ALAD-1 subunit in vitro. 
Epidemiologic studies have suggested that
among lead-exposed workers and environ-
mentally exposed children (7–9), individuals
with either the ALAD 1-2 or 2-2 genotype
had blood lead levels that were significantly
higher than those of individuals with the
ALAD 1-1 genotype. These findings suggest
that the ALAD-2 polypeptide binds lead more
tightly and effectively than does ALAD-1.
Recently, two occupational epidemiologic
studies in 691 members of a construction
union and 89 lead-smelter workers have indi-
cated that ALAD genotype may modify the
effect of lead on uricemia and kidney dysfunc-
tion (10,11). In this study, we attempted to
investigate the impact of ALAD polymor-
phism on the relationship of lead levels in
both blood and bone to uricemia and kidney
dysfunction among environmentally exposed
men. Our a priori hypothesis was that our
lead biomarkers would be independently cor-
related with hyperuricemia and renal dysfunc-
tion and that the ALAD variant type would
modify this effect, particularly when blood
lead or bone lead levels are high (12,13).
Methods
Participants. The Normative Aging Study
(NAS) is a longitudinal study of aging estab-
lished by the Veterans Administration in
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In this study we investigated whether a known δ-aminolevulinic acid dehydratase (ALAD) exon 4
polymorphism has a modifying effect on the association of blood or bone lead level with uricemia
and indices of renal function among middle-aged and elderly men. We performed a cross-sectional
study of subjects who participated between 1991 and 1995 in the Department of Veterans Affairs
Normative Aging Study. Information on blood lead levels, bone lead levels (measured by K-shell
X-ray ﬂuorescence), serum uric acid, serum creatinine, estimated creatinine clearance, and ALAD
polymorphism status was available in 709 subjects. Regression models were constructed to exam-
ine the relationships of serum uric acid, serum creatinine, and estimated creatinine clearance to
blood or bone lead level, stratiﬁed by genotype. We also adjusted for age, body mass index, blood
pressure, smoking, alcohol consumption, and ingestion of analgesic medications (n = 638). Of the
709 subjects, 7 (1%) and 107 (15%) were homozygous and heterozygous for the variant
(ALAD-2) allele, respectively. The mean (range) serum uric acid and creatinine levels were 6.5
(2.9–10.6) and 1.2 (0.6–2.5) mg/dL. No significant differences were found in serum uric acid,
serum creatinine, or estimated creatinine clearance by ALAD genotype. However, after adjusting
for other potential confounders, we found a signiﬁcant linear relationship between serum uric acid
and patella bone lead (p = 0.040) among the ALAD 1-2/2-2 genotype individuals above a thresh-
old patellar lead level of 15 µg/g. In contrast, among the wild-type (ALAD 1-1) individuals, there
was a suggestion of a signiﬁcant linear relationship of serum uric acid with patella bone lead (p =
0.141), but only after a threshold of 101 µg/g. There was evidence of a significant (p = 0.025)
interaction of tibia lead with genotype (ALAD 1-1 vs. ALAD 1-2/2-2) regarding serum creatinine
as an outcome, but in the same linear regression model tibia lead alone was not a signiﬁcant pre-
dictor of serum creatinine. Conversely, for estimated creatinine clearance, patella lead, but not the
interaction of patella lead with genotype, was a signiﬁcantly independent predictor (p = 0.026).
Our ﬁndings suggest that ALAD genotype may modify the effect of lead on the renal excretion of
uric acid as well as overall renal function among middle-aged and elderly men who had commu-
nity (nonoccupational) exposures to lead. Additional research is needed to ascertain whether this
constitutes a true gene–environment interaction and, if so, its clinical impact. Key words: δ-
aminolevulinic acid dehydratase, bone lead, serum creatinine, serum uric acid. Environ Health
Perspect 111:335–340 (2003). doi:10.1289/ehp.5504 available via http://dx.doi.org/ [Online
31 October 2002]
Environmental Medicine Articles1963 (14). Healthy male volunteers from the
Greater Boston, Massachusetts, area were
screened at entry and accepted into the study
if they had no history of heart disease, hyper-
tension, diabetes mellitus, cancer, peptic
ulcer, gout, recurrent asthma, bronchitis, or
sinusitis. Men with either systolic blood pres-
sure > 140 mm Hg or diastolic blood pressure
> 90 mm Hg at entry were disqualified.
Between 1963 and 1968, a total of 2,280
men who met the entry criteria were enrolled,
ranging in age from 21 to 80 years, with a
mean age of 42 years at entry. Study partici-
pants were asked to return for examinations
every 3–5 years. At each visit, extensive physi-
cal examination, laboratory, anthropometric,
and questionnaire data were collected.
Beginning in 1991, during the course of each
continuing participant’s regularly scheduled
evaluation at the Department of Veterans
Affairs outpatient clinic in Boston, a fresh
blood specimen was obtained for measure-
ment of lead and other biochemical indicators
such as uric acid and serum creatinine after an
overnight fast and abstinence from smoking,
and permission was sought to take bone lead
measurements by K-shell X-ray fluorescence
(KXRF). Consenting individuals reported to
the outpatient Clinical Research Center of the
Brigham and Women’s Hospital in Boston.
This study was approved by the Human
Subjects Committees of the Brigham and
Women’s Hospital and the Harvard School of
Public Health.
Uric acid and renal function. Serum uric
acid levels were measured by the colorimet-
ric phosphotungstic method (N-30) with
the Technicon Autoanalyzer (Technicon
Instruments, Tarrytown, NY, USA) (15).
The assay included standards from the College
of American Pathologists. In addition, the
correlation between the NAS colorimetric
phosphotungstic method and the more spe-
ciﬁc urease method at the clinical laboratory
of the Massachusetts General Hospital in 23
split serum samples was 0.93, indicating that
these two methods are comparable (15,16).
Serum creatinine was measured by an
Astra 8 analyzer (Beckman Instruments, Inc.,
Fullerton, CA, USA) (17). Creatinine clear-
ance was estimated on the basis of the serum
creatinine concentration according to the
method of Cockcroft and Gault (18). The fol-
lowing formula predicts creatinine clearance
from serum creatinine:
Derivation included the relation between age
and 24-hr creatinine excretion per kilogram
of body weight (19).
Blood and bone lead measurements. Blood
lead was measured by ESA Laboratories, Inc.
(Chelmsford, MA, USA) (20). In tests on
reference samples from the U.S. Centers for
Disease Control and Prevention, precision
(coefﬁcient of variation) ranged from 8% for
concentrations below 30 µg/dL to 1% for
higher concentrations. Measurements below
a concentration of lowest detection limit (1.0
µg/dL) were coded at 0.5 µg/dL (seven study
subjects).
Bone lead measurements were taken of
each subject’s mid-tibia shaft and patella using
an ABIOMED KXRF instrument (ABIO-
MED, Inc., Danvers, MA, USA). The physical
principles, technical speciﬁcations, validation,
and quality control procedures of this instru-
ment have been described in detail elsewhere
(20,21). Brieﬂy, the ﬂuorescent photons from
both bone lead and calcium were counted
simultaneously to provide the measurement of
lead concentration per unit of bone mineral
(microgram per gram). Although the KXRF
instrument may generate negative point esti-
mates of bone lead when the true values are
close to zero, we have found that retention of
all point estimates make better use of the data
in epidemiologic studies (21). In addition,
only three and one study subjects were found
to have the negative values for tibia and patella
lead levels, respectively. The technicians who
measured the bone lead were blind to the par-
ticipant’s health status.
ALAD exon 4 genotype analysis. The
ALAD polymorphism in exon 4 was deter-
mined by polymerase chain reaction (PCR)
with restriction fragment length polymor-
phism, according to the methods described
by Schwartz et al. (22). We performed PCR
reactions in duplicate, with blank controls
included in each set.
Statistical analyses. We ﬁrst compared the
distribution of demographic and lifestyle char-
acteristics, bone and blood lead levels, and
uric acid and renal function (serum creatinine
and estimated creatinine clearance) by geno-
type (ALAD 1-2/2-2 vs. ALAD 1-1) using chi-
squared and Student’s t-test statistics. Because
only 7 (1%) subjects in this population were
ALAD 2-2, our ability to distinguish between
effects associated with the ALAD 1-2 versus
the ALAD 2-2 genotypes was limited.
Nevertheless, initial analyses were conducted
comparing wild-type (ALAD 1-1) with ALAD
2-2 individuals alone to see if the homozygous
condition was associated with effects that were
obscured by combining the ALAD 2-2 and
ALAD 1-2 individuals. No such effects were
seen; thus, all later analyses were conducted
and reported combining ALAD 1-2 and
ALAD 2-2 into one category (ALAD 1-2/2-2).
Multivariate linear regression was used to
model determinants of uric acid and renal
function that started with core models
including determinants we had identified in
previously published studies (15,19). For uric
acid (milligrams per deciliter), these core-
model determinants included age (years),
body mass index [weight (kilograms)/height
(meters)2], log-transformed alcohol consump-
tion (grams per day), diastolic blood pressure
(milligrams mercury), and serum creatinine
(milligrams per deciliter); for serum creati-
nine and estimated creatinine clearance, these
core-model determinants included age, body
mass index, log-transformed alcohol con-
sumption, hypertension (yes/no), current
smoking (yes/no), former smoking (yes/no),
and use of analgesic medications (yes/no).
Then, blood lead, tibia lead, or patella lead
levels were separately forced into the models.
To assess whether genotype may serve as
an effect modiﬁer (vs. an independent deter-
minant) of the relationships of blood or bone
lead to uric acid and renal function, each of
these regressions was then repeated after
adding an interaction term for blood or bone
lead and genotype (ALAD 1-2/2-2 vs. ALAD
1-1). In addition, we also compared the coefﬁ-
cients of core-model and lead biomarker
determinants in regressions of uric acid and
renal function that were stratiﬁed by genotype
(ALAD 1-2/2-2 vs. ALAD 1-1). In each of the
above regressions, generalized additive models
(23) were to examine the shape of associations
between continuous variables (e.g., blood or
bone lead) and uric acid and renal function.
These analyses allowed us to assess for poten-
tial nonlinearities and the need for transform-
ing these covariates. Finally, we applied
statistical tests to determine whether a thresh-
old exists between blood or bone lead levels
and uric acid or renal function. Akaike’s
Information Criterion was computed to
determine the break point (24). Failure to
identify a threshold (break point), if one
exists, would erroneously attribute a relation-
ship at low blood or bone lead levels where it
is not present (25,26). In addition, such fail-
ure would underestimate both the size and
signiﬁcance of the effect at blood or bone lev-
els where it is truly present, by averaging lev-
els where the relationship is nonexistent with
those where it is significant. All data were
analyzed using the SAS (SAS Institute, Cary,
NC, USA) and S-PLUS (Insightful Corp,
Seattle, WA, USA) statistical packages. All
p-values reported are two sided.
Results
Between 1991 and 1995, there were 1,194
active NAS subjects, of whom 776 partici-
pated in the KXRF bone lead study. Of these,
710 subjects had all information on serum
uric acid and creatinine levels, genotype sta-
tus, and blood and bone lead levels. One sub-
ject with a serum creatinine of 9.0 mg/dL
(severe renal disease) was excluded (19). No
significant differences were found with
respect to the distributions of age, body mass
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pressure, current smoking status, and blood
and bone lead levels among subjects with and
without all information (n = 709 vs. 66) on
serum uric acid and creatinine, genotype sta-
tus, and blood and bone lead (data not
shown). Therefore, the subsequent analyses
were focused on the 709 study subjects.
The prevalence (number) of ALAD 1-1,
ALAD 1-2, and ALAD 2-2 was 83.9% (595),
15.1% (107), and 1.0% (7), respectively.
Table 1 shows the demographic characteristics,
blood and bone lead levels, and serum uric
acid and creatinine and estimated creatinine
clearance categorized by genotype. Except for
age, alcohol consumption, current smoking
status, diastolic blood pressure, and blood lead
levels, there were no meaningful differences of
characteristics by genotype. Subjects with
ALAD 1-2/2-2 genotype had a slightly older
mean age (68.1 years) and a slightly higher
diastolic blood pressure (83.2 mm Hg) than
those of the ALAD 1-1 genotype subjects
(66.8 years and 80.8 mm Hg). Conversely,
the ALAD 1-1 genotype was associated with a
higher percentage of current smokers than the
ALAD 1-2/2-2 genotype. Blood lead levels in
this population were relatively low, as
expected, with a mean ± SD of 6.2 ± 4.1
µg/dL. We found that mean blood lead level in
ALAD 1-1 subjects was slightly and signifi-
cantly higher than that in ALAD 1-2/2-2 indi-
viduals (p = 0.044). The same results were not
noted with respect to mean bone lead levels by
genotype. The mean ± SD serum uric acid and
creatinine were 6.5 ± 1.3 and 1.2 ± 0.2 mg/dL,
respectively, for all subjects. We did not ﬁnd
any meaningful difference in mean serum uric
acid, serum creatinine, or estimated creatinine
clearance between the allele groups.
Our hypotheses were that a) blood lead or
bone lead level was a risk factor for hyper-
uricemia and renal dysfunction and b) ALAD
variant type modified this effect especially
when blood lead or bone lead level was rela-
tively high (12,27). Table 2 shows the relation-
ship of serum uric acid with bone lead level
(patella or tibia lead) with and without an
additional term for the interaction of bone lead
with genotype, and before (n = 709) and after
(n = 638, because of missing data in body mass
index, alcohol consumption, and diastolic
blood pressure) adjusting for other potential
confounders identiﬁed in our previous investi-
gation (15). Bone lead level marginally 
predicted uric acid level after adjusting for age,
body mass index, alcohol consumption, dias-
tolic blood pressure, and serum creatinine
level (for patella lead, p = 0.078; for tibia lead,
p = 0.190; Table 2). When the interaction of
patella lead and genotype was added to the
regression model, the predictive slope coefﬁ-
cients of serum uric acid by patella or tibia
lead level in ALAD 1-2/2-2 individuals was
about 50–100% higher than that of ALAD 1-
1 subjects (β = 0.006 vs. 0.004 for patella lead
and β = 0.009 vs. 0.004 for tibia lead), but the
signiﬁcance levels of the terms were marginal.
When we reset the negative values of tibia and
patella lead (of which there were only four) to
zero, the results were almost identical. We did
not ﬁnd any signiﬁcant relation of blood lead
or its interaction with genotype to serum uric
acid (data not shown).
Table 3 shows the relationship of serum
creatinine or estimated creatinine clearance
with bone lead level with and without an
interaction term for bone lead and genotype
and before (n = 709) and after (n = 670,
because of 39 missing data in body mass
index and alcohol consumption) adjusting for
other potential confounders identiﬁed in our
previous investigation (19). Although bone
lead level signiﬁcantly predicted serum creati-
nine in the crude analysis, we found no sig-
nificant independent effect of either blood
lead or bone lead (tibia lead or patella lead) to
serum creatinine after adjusting for age, body
mass index, alcohol consumption, hyperten-
sion, current smoking status, and current
analgesic medications. However, we found a
significant interaction of tibia lead (but not
blood lead or patella lead) and genotype in
relation to serum creatinine (p = 0.025), even
though tibia lead level was not a significant
independent predictor (Table 3). For esti-
mated creatinine clearance, patella lead was a
signiﬁcant predictor (p = 0.024) after adjust-
ing for age, body mass index, alcohol con-
sumption, hypertension, current smoking
status, and current analgesic medications.
Neither tibia lead nor blood lead signiﬁcantly
predicted estimated creatinine clearance after
adjusting for other covariates. In addition, no
interaction was found of blood lead or bone
lead with genotype in relation to estimated
creatinine clearance (Table 3).
In a smoothed plot of serum uric acid in
relation to bone lead that is stratiﬁed by geno-
type and adjusted for other covariates in the
model (Figure 1), there is a suggestion of a
threshold effect, especially with respect to
patella lead, with break points among ALAD
1-1 and 1-2/2-2 genotype individuals at patella
lead levels of 101 µg/g and 15 µg/g, respec-
tively, based on the Akaike’s Information
Criterion (24). Using “hockey stick” regression
analyses (25,26), we found a signiﬁcant linear
relationship of serum uric acid with patella
lead (p = 0.040; Table 4) above the apparent
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Table 1. Demographic characteristics and blood and bone lead concentrations by genotypes among 709
study subjects, 1991–1995.
Genotype [mean ± SD (range)]
Total ALAD 1-1 ALAD 1-2/2-2
Variable (n = 709) (n = 595) (n = 114) p-Valuea
Age (years) 67.0 ± 7.4 66.8 ± 7.3 68.1 ± 7.5 0.075
(48.0–93.0) (48.0–93.0) (52.0–93.0)
Body mass index (kg/m2)b  27.8 ± 3.9 27.7 ± 3.8 28.3 ± 4.3 0.214
(16.7–44.9) (16.7–44.9) (18.8–41.5)
Diastolic blood pressure (mmHg)c  81.2 ± 9.8 80.8 ± 9.7 83.2 ± 9.9 0.021
(51.0–119.0) (51.0–119.0) (64.0–106.0)
Alcohol consumption (g/day)c  12.9 ± 17.5 13.5 ± 17.9 9.3 ± 14.7 0.011
(0–103.9) (0–103.9) (0–77.9)
Blood lead (µg/dl) 6.2 ± 4.1 6.3 ± 4.1 5.8 ± 4.2 0.044d
(0–35) (0–35) (0–27)
Bone lead (µg/g)
Tibia 22.0 ± 13.4 22.1 ± 13.9 21.5 ± 11.0 0.816e
(–3–126) (–3–126) (3–67)
Patella 32.1 ± 19.5 32.2 ± 20.0 31.1 ± 17.0 0.612e
(–10–165) (1–165) (–10–85)
Uric acid (mg/dL) 6.5 ± 1.3 6.4 ± 1.3 6.6 ± 1.3 0.211
(2.9–10.6) (2.9–10.6) (3.6–9.7)
Serum creatinine (mg/dL) 1.2 ± 0.2 1.2 ± 0.2 1.3 ± 0.3 0.222
(0.6–2.5) (0.6–2.5) (0.6–2.4)
Estimated creatinine clearance (mL/min)b  71.3 ± 21.2 71.6 ± 20.8 70.0 ± 23.3 0.472
(16.9–215.7) (24.1–215.7) (16.9–130.4)
Hypertension [n (%)]
Yes 528 (74.5) 445 (74.8) 83 (72.8) 0.656f
No 181 (25.5) 150 (25.2) 31 (27.2)
Current smoking status [n (%)]
Never smoker 215 (30.3) 174 (29.2) 41 (36.0) 0.016g
Former smoker 432 (60.9) 362 (60.8) 70 (61.4)
Current smoker 62 (8.7) 59 (9.9) 3 (2.6)
Current analgesic medications
Yes 538 (75.9) 450 (75.6) 88 (77.2) 0.721f
No 171 (24.1) 145 (24.4) 26 (22.8)
aDetermined by Student’s t-test except where noted. b Three missing in ALAD 1-1 and one missing in ALAD 1-2/2-2.
cTwenty-seven missing in ALAD 1-1 and nine missing in ALAD 1-2/2-2. dDetermined by Student’s t-test after taking the
natural logarithm of blood lead. eDetermined by Student’s t-test after adding the value of 35 and then taking the natural
logarithm of all values. fChi-square test. gFisher’s exact test.patella lead threshold level of 15 µg/g among
the ALAD 1-2/2-2 genotype individuals, but
not among the ALAD 1-1 genotype individu-
als above the apparent patella lead level of
101 µg/g (p = 0.141).
Discussion
We have previously demonstrated that the
patella lead level is independently associated
with serum uric acid (15). In the present
study, our sample was slightly different and
the independent effect of patellar lead on
serum uric acid was only of marginal signiﬁ-
cance (p = 0.078); however, we found a signif-
icant linear relationship of serum uric acid
with patella lead among ALAD 1-2/2-2 geno-
type individuals who had patella lead levels
greater than an apparent threshold of 15 µg/g.
There was also a suggestion of a linear rela-
tionship of serum uric acid with patella lead
among ALAD 1-1 genotype individuals, but
with a much higher apparent threshold (~101
µg/g); moreover, the regression coefﬁcient for
patella was not signiﬁcant.
This difference between the ALAD
1-2/2-2 and ALAD 1-1 individuals is fairly
striking, and suggests that ALAD status
modifies the relationship between lead and
hyperuricemia with ALAD 1-2/2-2 individ-
uals having a higher risk for lead-induced
hyperuricemia. On the other hand, there
were relatively few subjects with patella lead
levels > 101 µg/g in this community-
exposed population (Figure 1). Similar
results were found with respect to tibia and
blood lead, but they were not as impressive
as those for patella lead. The ALAD-2 vari-
ant individuals had about a 0.5–2-fold
higher serum uric acid than did those with
the wild-type ALAD 1-1 (Table 2).
Hyperuricemia is the strongest risk factor
for gout. Campion et al. (16) found an
increased incidence of gout with serum uric
acid levels > 9.0 mg/dL. Among patients with
lead nephropathy, there is no evidence of over-
production of uric acid (28,29). Therefore,
chronic lead toxicity causes hyperuricemia
mainly due to a defect in the tubular secretion
of uric acid. In this study, we found an associa-
tion between hyperuricemia and bone lead,
especially patella lead. Toxic levels of lead (e.g.,
blood lead levels > 60 µg/dL) are clearly associ-
ated with gouty arthritis (15,28). However, to
what extent low-level lead exposure contributes
to the development of hyperuricemia and clin-
ical risk of gout is unclear. The middle-aged
and elderly men in this cohort currently have
low levels of lead in blood (mean, 6.2 µg/dL),
which may help to explain why our results are
not stronger.
Studies in humans have indicated that
renal function may be impaired by high levels
of lead exposure or prolonged low-level lead
exposure (2,19). Renal biopsies in humans
with long-term high lead exposure have
revealed abnormal renal peritubular and inter-
stitial ﬁbrous tissue. Lead-induced interstitial
nephritis could lead to a true reduction in the
glomerular ﬁltration rate or could alter factors
that influence the glomerular filtration rate
(e.g., surface area, permeability, and oncotic
and hydrostatic pressure gradients across the
capillary walls) (30). In this cross-sectional
study, bone lead level (tibia or patella lead) was
positively associated with serum creatinine, but
these results did not reach significance after
adjusting for other covariates. On the other
hand, we detected a positive and significant
interaction of tibia lead (but not patella lead)
with ALAD genotype in relation to serum crea-
tinine (Table 3), showing ALAD-2 subjects
had about 3–4-fold higher serum creatinine
than did individuals with ALAD-1. This ﬁnd-
ing suggests that ALAD may modify the
chronic renal toxicity of lead. In a similar vein,
Bergdahl et al. (11) did not ﬁnd any modifying
effect of ALAD genotype on the relationship of
lead to clinical kidney disease indicators among
89 lead-exposed workers, but they did find
that the concentrations of urinary calcium and
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Table 3. Relationship of serum creatinine or estimated creatinine clearance with bone lead (µg/g) without and with ALAD genotype interaction in the Normative
Aging Study, 1991–1995.
Crude analyses (n = 709) Adjusted analyses (n = 670)a
Regression Regression Regression Regression
Variable coefﬁcient p-Value coefﬁcientb p-Value coefﬁcient p-Value coefﬁcientb p-Value
Serum creatinine (mg/dL)
Patella 
Lead 0.001 0.021 0.0008 0.053 0.0004 0.408 0.0003 0.518
Lead–ALADc —— 0.002 0.024 — — 0.0009 0.172
Tibia 
Lead 0.002 0.019 0.001 0.055 0.0006 0.354 0.0005 0.495
Lead–ALADc —— 0.003 0.003 — — 0.002 0.025
Estimated creatinine clearance (mL/min)
Patella
Lead –0.190 < 0.001 –0.186 < 0.001 –0.069 0.024 –0.069 0.026
Patella Lead–ALADc —— –0.042 0.485 — — –0.006 0.884
Tibia
Lead –0.271 < 0.001 –0.263 < 0.001 –0.078 0.082 –0.075 0.098
Lead–ALADc —— –0.090 0.310 — — –0.044 0.499
aAdjusted for age (years), body mass index, hypertension (yes/no), current smoking (yes/no), former smoking (yes/no), log-transformed alcohol intake (g/day), and current analgesic
medications (yes/no); some variables have missing data. bLead–ALAD interaction in the regression model. cInteraction between genotype (ALAD 1-2/2-2 vs. ALAD 1-1).
Table 2. Relationship of uric acid (mg/dL) with bone lead (µg/g) in multivariate linear regression without and with ALAD genotype interaction in the Normative
Aging Study, 1991–1995. 
Crude analyses (n = 709) Adjusted analyses (n = 638)a
Regression Regression Regression Regression
Variable coefﬁcient p-Value coefﬁcientb p-Value coefﬁcient p-Value coefﬁcientb p-Value
Patella
Lead 0.005 0.048 0.004 0.093 0.005 0.078 0.004 0.129
Lead–ALADc —— 0.007 0.074 — — 0.006 0.089
Tibia
Lead 0.006 0.089 0.005 0.169 0.005 0.190 0.004 0.274
Lead–ALADc —— 0.012 0.028 — — 0.009 0.080
aAdjusted for age (years), body mass index index, log-transformed alcohol consumption (g/day), diastolic blood pressure (mm Hg), and serum creatinine (mg/dL); some variables have
missing data. bLead–ALAD interaction in the regression model. cInteraction between bone lead and genotype (ALAD 1-2/2-2 vs. ALAD 1-1).the ratio of urinary creatinine/serum creatinine
were signiﬁcantly lower in the seven ALAD 1-
2/2-2 subjects compared with those of the 82
ALAD 1-1 lead workers [median urinary cal-
cium (mg/L), 76 vs. 188; urinary creatinine/
serum creatinine ratio, 84 vs. 180]. Thus, their
study did suggest the presence of ALAD allele-
specific differences in kidney function. In
another study, Smith et al. (10) investigated
the association between the presence of ALAD-
2 allele, renal function, and lead concentra-
tions in blood and bone among 688 members
of a construction trade union. They found
marginally higher levels of blood urea nitrogen
(p = 0.06) and uric acid (p = 0.09) among the
ALAD-2 genotype individuals after adjusting
for blood lead level, age, and alcohol consump-
tion. Smith et al. (10) suggested that ALAD-2
genotype may inﬂuence chronic renal toxicity
by differential binding of lead to the variant
ALAD-2 protein. Our results are consistent
with these previous reports in demonstrating
that ALAD genotype status may modify the
relationship between lead and kidney function.
In addition to our findings with serum
creatinine, we observed that creatinine clear-
ance, estimated by age, body weight, and
serum creatinine, is significantly and nega-
tively associated with bone lead, especially
patella lead. One possible explanation is that
serum creatinine is not as sensitive a marker
for subclinical renal damage as is estimated
creatinine clearance. Notably, Nolan and
Shaikh (30) found that N-acetyl-D-glu-
cosaminidase, a lysosomal marker of tubular
cell toxicity, is a sensitive marker for detecting
subclinical kidney damage and is associated
with blood lead levels.
We did not find any significant associa-
tion between blood lead and impaired renal
function as measured by serum creatinine or
estimated creatinine clearance. Current blood
lead level does not represent long-term lead
exposure, which may explain why it is not an
adequate dosimeter with respect to kidney
toxicity. Regarding our measures of bone lead,
it is not clear why we found that patella bone
lead was the best predictor of elevated serum
uric acid whereas tibia bone lead was the best
predictor of elevated serum creatinine.
Compared with the patella, which is com-
posed mostly of trabecular bone, the tibia is
mostly cortical bone with a slow rate of bone
turnover and a longer half-life with respect to
lead levels. As a consequence, the tibia is a bet-
ter reflection of long-term cumulative lead
exposure, whereas the high resorption rates of
trabecular bone make it the most important
skeletal source of circulating lead (31). It is
possible that lead-induced rises in serum uric
acid are mostly dependent on active resorp-
tion of bone lead stores, whereas lead-induced
rises in serum creatinine are mostly dependent
on a cumulative effect of lead on the kidney
taking place over many years.
How might this ALAD polymorphism
modify the impact of lead on uric acid? The
effect of lead on uric acid metabolism has
been thought to be mediated by a toxic effect
on the proximal renal tubule, which is the site
of uric acid excretion as well as active secretion
by renal tubular cells. It is possible that the
lead–ALAD-2 subunit complex is more toxic
to proximal tubular cells than is the
lead–ALAD-1 subunit (11). This same mecha-
nism might be more broadly explanatory of a
modifying effect of the ALAD polymorphism
on general kidney function, as reﬂected by our
ﬁndings with respect to serum creatinine.
Although in in vitro studies and epidemio-
logic studies suggest that the ALAD-2 polypep-
tide binds lead more tightly and effectively
than does ALAD-1 (3,7,8), the theoretical dif-
ferential binding of lead by the ALAD iso-
enzymes does not indicate greater susceptibility
to lead for persons with the ALAD-2 genotype.
Susceptibility is dependent on different parti-
tioning of lead and how bioavailable different
complexed forms of lead are in different tis-
sues. In the present study, ALAD-2 modiﬁed
lead’s relation to uricemia and indices of renal
function. However, the modifying inﬂuence of
ALAD polymorphism on the neurologic effect
of lead may be different (12,32). An elevated
concentration of plasma δ-aminolevulinic acid,
an early biologic effect of lead poisoning, was
higher in 44 battery workers with homozygous
ALAD-1, compared with 21 ALAD-2 workers
(12). Sithisarankul et al. (12) suggested that if
the neurologic effects of lead poisoning are
partly due to elevated δ-aminolevulinic acid,
then the ALAD-2 genotype may be protective
for this end point. This is consistent with the
results of a study of neuropsychologic effects
of lead in adolescents, showing that the
ALAD-2 subjects performed better on tests of
attention than did the ALAD-1 subjects after
adjusting for lead exposure (32). These poten-
tial contrasting roles of ALAD genotype
demand further study to clarify the effect of
susceptibility to lead toxicity.
Our study has a number of limitations
including its cross-sectional epidemiologic
design and, perhaps most important, its focus
on community-exposed men with relatively
modest lead burdens, as reflected by bone
lead levels less than a third of those seen in
workers in a primary lead industry, such as
lead smelting (11,33). It is quite possible that
the modifying effect of ALAD polymorphism
on lead toxicity would be more apparent
among populations with higher levels of lead
exposure. Clearly, our findings must be
viewed only as suggestive, and other studies
are needed to see if these relationships can be
replicated.
In conclusion, we found evidence that a
polymorphism of ALAD that has been the
recent focus of research may modify the
impact of lead on uric acid excretion and gen-
eral kidney function, with ALAD-2 carriers
manifesting effects at levels of lead burden with
an apparently lower threshold than that of
ALAD 1-1 individuals. Additional research is
required to determine if this represents a true
gene–environment interaction with clinical
signiﬁcance.
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